Avid Bioservices Inc (CDMO)

[skweze]

Aside from the unique labeling fiasco setback, I see similarities in the trajectories of PPHM and MEDX (but PPHM seems to have more indications and a more valuable IP portfolio), not the least of which is the same nonsense from the same "journalists" in the financial media. Let's hope the trajectories don't end the same way with a cheap buyout from BMY!

Another was the BOD's admitted failure to require GS, MEDX' retained financial advisor, to place a value on the 78 or so patents and other IP held by MEDX to protect its pipeline in the course of opining that the $16 share price was fair value.